EUDA Health Holdings Limited filings document the company as a Nasdaq-listed foreign private issuer operating a Singapore-based healthcare business focused on non-invasive, preventive and longevity-oriented services in Asia. Form 6-K reports disclose business updates involving stem cell and cellular therapy arrangements, commercial distribution rights, and related healthcare platform expansion.
The filing record also covers capital-structure and governance matters, including ordinary share offerings under a Form F-3 registration statement, warrant issuances, amendments, repurchase and cancellation, a reverse stock split, Nasdaq market-value compliance notices, and amendments to the company's BVI constitutional documents.
EUDA Health Holdings Limited filed a Form 6-K highlighting that Shenzhen Inno Immune Co., Ltd. has received official approval under the 2025 Shenzhen Key Industry R&D Program for a TCR-T cell therapy project targeting solid tumors.
The project is scheduled to run from January 1, 2026 to December 31, 2028 and may receive up to approximately US$434,688 in government funding from the Shenzhen Science and Technology Innovation Bureau. Under a non-exclusive distribution arrangement, EUDA holds rights to market and sell selected Shenzhen Inno immunotherapies to customers in Malaysia via its subsidiary CK Health Plus Sdn Bhd, with treatments conducted in China.
Management explains that this aligns with EUDA’s strategy to expand access to advanced, science-driven therapies and supports its broader focus on preventive and longevity-focused healthcare across Asia.
EUDA Health Holdings Limited files its annual Form 20-F for the year ended December 31, 2025, highlighting ongoing financial strain and strategic shifts. The company reports a net loss of approximately $2.8 million for 2025, following a $15.4 million loss in 2024, and discloses a working capital deficit of about $4.8 million with only $0.3 million in cash.
EUDA’s auditor raises substantial doubt about its ability to continue as a going concern, and management acknowledges material weaknesses in internal control over financial reporting. Nasdaq has notified the company that it failed to maintain the required $35 million Minimum Market Value of Listed Securities; EUDA must regain compliance by October 20, 2026 to avoid potential delisting.
The report describes a strategic move from medical services to wellness, including the $15.0 million all-share acquisition of CK Health, which generated roughly $2.0 million of 2025 revenue, and reliance on Southeast Asian wellness and planned stem cell offerings. EUDA also details multiple equity and convertible financings, a 1-for-20 reverse stock split, and an agreement to purchase 16 million QB utility tokens using cash and shares, underscoring its need for ongoing external funding.
EUDA Health Holdings Limited reported that Nasdaq notified the company on April 23, 2026 that it failed to maintain the required Minimum Market Value of Listed Securities of $35 million for 32 consecutive business days under Nasdaq Listing Rule 5550(b)(2). The notice does not immediately affect trading, and EUDA has 180 calendar days, until October 20, 2026, to regain compliance by having its market value close at $35,000,000 or more for at least ten consecutive business days. If EUDA does not regain compliance within this period, its securities will be subject to potential delisting, although the company would have the right to appeal.
EUDA Health Holdings Limited approved and is implementing a 1-for-20 reverse stock split of its ordinary shares, effective at market open on March 23, 2026 on the Nasdaq Capital Market. The company states that shareholder ownership percentages and voting power will remain substantially the same aside from minor rounding effects.
Shares outstanding will be reduced from approximately 50,307,491 to approximately 2,515,375, with fractional shares rounded up and no cash paid in lieu. EUDA’s outstanding warrants will be adjusted proportionately, cutting underlying shares from about 4,458,625 to about 222,932 while increasing the exercise price from $11.50 to $230.00 per share equivalent.
EUDA Health Holdings Ltd Chief Financial Officer Tay Whye Shin has filed an initial Form 3, which is a required statement of beneficial ownership for company insiders. The filing establishes this officer’s reporting status under SEC rules but does not report any stock transactions.
EUDA Health Holdings Ltd director Liew Kwong Yeow filed an initial ownership report showing direct holdings of 3,000 Ordinary Shares. This Form 3 does not report any recent buy or sell transactions; it simply establishes his current equity stake in the company.
EUDA Health Holdings Ltd director Lew Chern Yong has filed a Form 3, which records his status as an insider of the company. The provided data does not list any equity transactions or derivative positions, and the transaction summary shows no buys, sells, or other reportable trades.
EUDA Health Holdings Ltd director Huang Bo filed an initial statement of beneficial ownership as a new insider. This Form 3 filing does not report any share purchases, sales, or other transactions, and instead serves to formally register Huang Bo’s status as a reporting person for EUDA Health.
EUDA Health Holdings Limited updated its corporate charter and removed a potential source of new shares. The company adopted an Amended and Restated Memorandum and Articles of Association that, among other changes, expressly allows its board or shareholders to divide or combine ordinary shares by resolution.
EUDA also repurchased for US$125,000 and cancelled a warrant previously issued to Streeterville Capital, LLC that had been immediately exercisable for up to 2,000,000 ordinary shares. The warrant is no longer outstanding, and the potential share issuance under this agreement has been fully eliminated.
EUDA Health Holdings Limited completed a registered offering of 12,500,000 ordinary shares for an aggregate purchase price of $3,750,000, using its Form F-3 shelf registration and a March 2026 prospectus supplement. The company plans to use the net proceeds for general corporate purposes, including possible acquisitions, business expansion and working capital.
Separately, EUDA repurchased in full a previously issued warrant that was exercisable for 2,000,000 newly issued ordinary shares, paying $125,000 on February 27, 2026, and the warrant was cancelled. The report also incorporates this information by reference into the company’s existing Form F-3 registration statement.